T-DM1 improved overall survival for heavily pretreated patients with HER2-positive br

[News]

Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb])...

More... (http://www.medicalnewstoday.com/releases/304018.php)